We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Date
- 2025 (20)
- 2024 (41)
- 2023 (48)
- 2022 (26)
- 2021 (101)
- 2020 (61)
- 2019 (126)
- 2018 (40)
- 2017 (22)
- 2016 (24)
- 2015 (14)
- 2014 (22)
- 2013 (8)
- 2012 (3)
- 2010 (2)
- 2009 (11)
- 2008 (5)
- 2007 (12)
- 2006 (10)
- 2005 (15)
- 2004 (5)
- 2003 (2)
- 2002 (6)
- 2001 (3)
- 2000 (12)
- 1999 (5)
- 1998 (4)
- 1997 (1)
- 1996 (7)
- 1995 (2)
- 1994 (6)
- 1993 (6)
- 1991 (20)
Sponsor content
690 result(s) found, displaying 51 to 60
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XENPOZYME olipudase alfa 20mg powder for injection vial.
-
Australian public assessment report (AusPar)Beyfortus (nirsevimab) has been approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season. It is also for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd